PMID- 28440022
OWN - NLM
STAT- MEDLINE
DCOM- 20180308
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 6
IP  - 6
DP  - 2017 Jun
TI  - MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous 
      cell carcinoma.
PG  - 1323-1330
LID - 10.1002/cam4.1026 [doi]
AB  - The aim of this study was to study the role of miR-372-3p in lung squamous cell 
      carcinoma (LSCC) cell proliferation and invasion by suppressing FGF9. RT-PCR was 
      used to determine miR-372-3p and FGF9 mRNA expression in tissues and cells. 
      Western blot was used to determine FGF9 expression in tissues and NCI-H520 cell 
      line. Dual luciferase reporter gene assay was conducted to confirm that FGF9 can 
      be directly targeted by miR-372-3p. MTT, colony formation assays were conducted 
      to investigate the effects of ectopic miR-372-3p and FGF9 expression on NCI-H520 
      cell growth. Flow cytometry was used to analyze the influence of miR-372-3p and 
      FGF9 expression on cell cycle distribution and apoptosis. Transwell assay was 
      also conducted to see the effects of miR-372-3p and FGF9 expression on NCI-H520 
      cell invasiveness. MiR-372-3p was found significantly overexpressed in both LSCC 
      tissues and cell lines, whereas FGF9 mRNA was found underexpressed in LSCC 
      tissues. MiR-372-3p directly bound to wild-type FGF9 mRNA 3'UTR, therefore led to 
      the reduction in FGF9 expression. The upregulation of FGF9 or the downregulation 
      of miR-372-3p substantially retarded LSCC cell growth, mitosis, and invasion. 
      MiR-372-3p enhanced LSCC cell proliferation and invasion through inhibiting FGF9.
CI  - (c) 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Wang, Qing
AU  - Wang Q
AD  - Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning, 110032, China.
FAU - Liu, Siyang
AU  - Liu S
AD  - Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning, 110032, China.
FAU - Zhao, Xitong
AU  - Zhao X
AD  - Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning, 110032, China.
FAU - Wang, Yuan
AU  - Wang Y
AD  - Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning, 110032, China.
FAU - Tian, Dali
AU  - Tian D
AD  - Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning, 110032, China.
FAU - Jiang, Wenjun
AU  - Jiang W
AUID- ORCID: 0000-0002-0227-5804
AD  - Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, Liaoning, 110032, China.
LA  - eng
PT  - Journal Article
DEP - 20170424
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (FGF9 protein, human)
RN  - 0 (Fibroblast Growth Factor 9)
RN  - 0 (MIRN372 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Apoptosis
MH  - Carcinoma, Squamous Cell/*genetics/metabolism/*pathology
MH  - Cell Cycle
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Fibroblast Growth Factor 9/*genetics/metabolism
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung/metabolism
MH  - Lung Neoplasms/*genetics/metabolism/*pathology
MH  - MicroRNAs/*genetics
MH  - RNA, Messenger/metabolism
PMC - PMC5463061
OTO - NOTNLM
OT  - LSCC
OT  - FGF9
OT  - MiR-372-3p
EDAT- 2017/04/26 06:00
MHDA- 2018/03/09 06:00
PMCR- 2017/04/24
CRDT- 2017/04/26 06:00
PHST- 2016/11/09 00:00 [received]
PHST- 2016/12/26 00:00 [revised]
PHST- 2017/01/06 00:00 [accepted]
PHST- 2017/04/26 06:00 [pubmed]
PHST- 2018/03/09 06:00 [medline]
PHST- 2017/04/26 06:00 [entrez]
PHST- 2017/04/24 00:00 [pmc-release]
AID - CAM41026 [pii]
AID - 10.1002/cam4.1026 [doi]
PST - ppublish
SO  - Cancer Med. 2017 Jun;6(6):1323-1330. doi: 10.1002/cam4.1026. Epub 2017 Apr 24.